Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

India Sued By Becton Dickinson Of U.S. Over Medical Device Bid Process

This article was originally published in PharmAsia News

Executive Summary

India's Health Ministry has been sued by the India unit of Becton Dickinson, a maker of medical devices in the United States, for violating India's own rules on bidding. Also named in the BD India suit was Hindustan Syringes & Medical Devices, Iscon Surgicals, both of India, and Wuxi Yushou Medical Appliances of China. The suit alleges the ministry canceled a tender while it was still open and floated a new one. BD India contends its bid was the lowest, yet the ministry intended to buy products from a competitor. The government said it had valid reasons for ending the first tender. (Click here for more

You may also be interested in...



FDA’s Cannabidiol Crackdown: What Do Warning Letters Say About CBD In Cosmetics?

Cannabidiol (CBD) represents an intriguing opportunity for cosmetics, without the statutory obstacles faced by food and dietary supplement companies. Cosmetics marketers are taking advantage, but the FDA’s recent warning letter blitz is a reminder that CBD-infused beauty products are bound by the same rules that apply to other cosmetics.

Acadia’s Nuplazid Shows Nearly Three-Fold Reduction In Psychosis Relapse

Data presented at the CTAD meeting for pimavanserin in dementia-related psychosis will support an sNDA filing in 2020 for an approval that could broaden the drug’s market exponentially.

Analyzing Quality Data Is Essential. Here’s What One Expert Says Your Firm Should Do To Stay In FDA’s Good Graces

Device makers should make sure they have adequate resources to analyze quality data they take in so they can prevent the recurrence of nonconforming products, processes and procedures. That’s just one nugget of advice from former FDA investigations branch director Ricki Chase, who explains why collecting and properly handling such data is critical to complying with agency expectations in this Medtech Insight Q&A interview.

UsernamePublicRestriction

Register

SC072304

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel